ACADIA Pharmaceuticals Inc.
ACAD
株式のランク
#4446
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
株価
$20.27
時価総額
$3.49B
変化（1日）
2.38%
変化（1年）
-3.20%
国
US
取引 ACADIA Pharmaceuticals Inc. (ACAD)
カテゴリー
Healthcare
ACADIA Pharmaceuticals Inc.（ACAD）のP/B比率
October 2026 時点のP/B比率 TTM: 2.53
ACADIA Pharmaceuticals Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 2.53 です。2023 年末時点でのP/B比率は 11.88 でした。
ACADIA Pharmaceuticals Inc. の P/B 比率の履歴（2000 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 2.53 | -39.08% |
| 2024 | 4.15 | -65.07% |
| 2023 | 11.88 | 84.80% |
| 2022 | 6.43 | -7.18% |
| 2021 | 6.93 | -48.37% |
| 2020 | 13.41 | 48.93% |
| 2019 | 9.01 | 110.82% |
| 2018 | 4.27 | -61.19% |
| 2017 | 11.01 | 70.82% |
| 2016 | 6.45 | -64.11% |
| 2015 | 17.96 | 80.01% |
| 2014 | 9.98 | -15.17% |
| 2013 | 11.76 | 291.77% |
| 2012 | 3.00 | 24.44% |
| 2011 | 2.41 | 54.65% |
| 2010 | 1.56 | -61.80% |
| 2009 | 4.08 | 547.88% |
| 2008 | 0.63 | -81.58% |
| 2007 | 3.42 | -6.39% |
| 2006 | 3.65 | -33.64% |
| 2005 | 5.51 | 141.07% |
| 2004 | 2.28 | -1,330.93% |
| 2003 | -0.19 | -23.53% |
| 2002 | -0.24 | -153.56% |
| 2001 | 0.45 | -242.26% |
| 2000 | -0.32 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | 147.25% |
US
|
|
| 13.2547 | 424.27% |
US
|
|
| 4.208 | 66.44% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 144.54% |
NL
|
